These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34717041)

  • 21. A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
    Vassiliou D; Sardh E; Harper P; Simon AR; Clausen VA; Najafian N; Robbie GJ; Agarwal S
    Clin Pharmacol Ther; 2021 Nov; 110(5):1250-1260. PubMed ID: 34510420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin.
    Lahiji AP; Anderson KE; Chan A; Simon A; Desnick RJ; Ramanujam VMS
    Mol Genet Metab; 2020 Dec; 131(4):418-423. PubMed ID: 33199206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA interference therapy in acute hepatic porphyrias.
    Yasuda M; Keel S; Balwani M
    Blood; 2023 Nov; 142(19):1589-1599. PubMed ID: 37027823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.
    To-Figueras J; Wijngaard R; García-Villoria J; Aarsand AK; Aguilera P; Deulofeu R; Brunet M; Gómez-Gómez À; Pozo OJ; Sandberg S
    J Inherit Metab Dis; 2021 Jul; 44(4):961-971. PubMed ID: 33861472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives.
    Marcacci M; Ricci A; Cuoghi C; Marchini S; Pietrangelo A; Ventura P
    Orphanet J Rare Dis; 2022 Apr; 17(1):160. PubMed ID: 35392955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria.
    Graff E; Anderson KE; Levy C
    Front Genet; 2022; 13():867856. PubMed ID: 35991568
    [No Abstract]   [Full Text] [Related]  

  • 27. Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report.
    Mazzoli M; Ricci A; Vaudano AE; Marcacci M; Marchini S; Bergonzini P; Di Pierro E; Pischik E; Iughetti L; Pietrangelo A; Meletti S; Ventura P
    Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3268-3274. PubMed ID: 38708485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks.
    Gouya L; Ventura P; Balwani M; Bissell DM; Rees DC; Stölzel U; Phillips JD; Kauppinen R; Langendonk JG; Desnick RJ; Deybach JC; Bonkovsky HL; Parker C; Naik H; Badminton M; Stein PE; Minder E; Windyga J; Bruha R; Cappellini MD; Sardh E; Harper P; Sandberg S; Aarsand AK; Andersen J; Alegre F; Ivanova A; Talbi N; Chan A; Querbes W; Ko J; Penz C; Liu S; Lin T; Simon A; Anderson KE
    Hepatology; 2020 May; 71(5):1546-1558. PubMed ID: 31512765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
    Petrides PE; Klein M; Schuhmann E; Torkler H; Molitor B; Loehr C; Obermeier Z; Beykirch MK
    Ann Hematol; 2021 Jul; 100(7):1685-1693. PubMed ID: 34050373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventing hyperhomocysteinemia using vitamin B
    Redonnet-Vernhet I; Mercié P; Lebreton L; Blouin JM; Bronnimann D; Mesli S; Guibet C; Ribeiro E; Gensous N; Duffau P; Gouya L; Richard E
    Mol Genet Metab Rep; 2024 Jun; 39():101076. PubMed ID: 38601120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved
    Li J; Liu J; Zhang X; Clausen V; Tran C; Arciprete M; Wang Q; Rocca C; Guan LH; Zhang G; Najarian D; Xu Y; Smith P; Wu JT; Chong S
    Drug Metab Dispos; 2021 Jul; 49(7):572-580. PubMed ID: 33941543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world annualized healthcare utilization and expenditures among insured US patients with acute intermittent porphyria (AIP) treated with hemin.
    Blaylock B; Epstein J; Stickler P
    J Med Econ; 2020 Jun; 23(6):537-545. PubMed ID: 31999204
    [No Abstract]   [Full Text] [Related]  

  • 33. Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran.
    Ventura P; Sardh E; Longo N; Balwani M; Plutzky J; Gouya L; Phillips J; Rhyee S; Fanelli MJ; Sweetser MT; Petrides PE
    Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):879-894. PubMed ID: 35929959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria].
    Stölzel U
    Z Gastroenterol; 2020 Aug; 58(8):785. PubMed ID: 32785915
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
    Sardh E; Rejkjaer L; Andersson DE; Harper P
    Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EXPLORE B: A prospective, long-term natural history study of patients with acute hepatic porphyria with chronic symptoms.
    Cassiman D; Kauppinen R; Monroy S; Lee MJ; Bonkovsky HL; Thapar M; Guillén-Navarro E; Minder AE; Hale C; Sweetser MT; Ivanova A
    J Inherit Metab Dis; 2022 Nov; 45(6):1163-1174. PubMed ID: 36069414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Givosiran - Running RNA Interference to Fight Porphyria Attacks.
    Gonzalez-Aseguinolaza G
    N Engl J Med; 2020 Jun; 382(24):2366-2367. PubMed ID: 32521139
    [No Abstract]   [Full Text] [Related]  

  • 38. Case-based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management.
    Balwani M; Keel S; Meissner P; Sonderup M; Stein P; Yasuda M
    Liver Int; 2024 Apr; ():. PubMed ID: 38618923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Overview of Acute Hepatic Porphyrias: Clinical Implications, Diagnostic Approaches, and Management Strategies.
    Zübarioğlu T; Kıykım E; Aktuğlu-Zeybek Ç
    Turk Arch Pediatr; 2023 Jan; 58(1):3-9. PubMed ID: 36598205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of delta-aminolevulinic acid in the symptoms of acute porphyria.
    Bissell DM; Lai JC; Meister RK; Blanc PD
    Am J Med; 2015 Mar; 128(3):313-7. PubMed ID: 25446301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.